Global Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI05241838

Publication Date:

June 5, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Ovarian cancer is the most common cause of mortality for women with gynecological cancers Additionally, it ranks as the seventh most common cause of mortality for females overall. The majority of instances are discovered when the disease has already progressed, which leads to poor outcomes. The cancer cells can be marked with a specific targeted therapy, making it simpler for the immune system to recognize and eliminate them. In addition, some targeted therapies can help in enhancing the immune system so that it fights cancer effectively which further boost the market growth.
The global Ovarian Cancer Targeted Therapy Drugs market size is projected to grow from US$ 1783 million in 2024 to US$ 2978 million in 2030; it is expected to grow at a CAGR of 8.9% from 2024 to 2030.
The 鈥淥varian Cancer Targeted Therapy Drugs Industry Forecast鈥� looks at past sales and reviews total world Ovarian Cancer Targeted Therapy Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Ovarian Cancer Targeted Therapy Drugs sales for 2023 through 2029. With Ovarian Cancer Targeted Therapy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ovarian Cancer Targeted Therapy Drugs industry.
This Insight Report provides a comprehensive analysis of the global Ovarian Cancer Targeted Therapy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Ovarian Cancer Targeted Therapy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Ovarian Cancer Targeted Therapy Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ovarian Cancer Targeted Therapy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ovarian Cancer Targeted Therapy Drugs.
Asia-Pacific expected to grow at the highest rate during the ovarian cancer drugs market forecast. The market growth in this region is attributable to presence of pharmaceutical companies in the region as well as growth in the purchasing power of populated countries, such as China and India. Moreover, rise in personalized medicine expenditure and adoption of high-tech processing to improve the production of ovarian cancer drugs, drive the growth of the market. In addition, high population base, presence of unmet medical needs, and increase in disposable incomes of people in the region further boost the market growth. Moreover, rise in medical tourism and developing healthcare infrastructure make Asia-Pacific a lucrative market for ovarian cancer drugs.Furthermore, increase in technological innovations in drug discovery, surge in funding provided by the government and private organizations, presence of large number of healthcare reforms, and increase in aging population of woman drive the growth of the market. Moreover, increase in demand for advanced healthcare services in emerging economies such as India and China are the major factors that drive the growth of the Asia-Pacific market. Asia-Pacific offers profitable opportunities for key players operating in the ovarian cancer drugs market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising disposable incomes, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.
This report presents a comprehensive overview, market shares, and growth opportunities of Ovarian Cancer Targeted Therapy Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
PARP Inhibitors
Angiogenesis Inhibitors
Others
Segmentation by Application:
Hospital Pharmacy
Drug Stores and Retail Pharmacy
Online Providers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
PARP Inhibitors
Angiogenesis Inhibitors
Others
Segmentation by Application:
Hospital Pharmacy
Drug Stores and Retail Pharmacy
Online Providers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck KGaA
GlaxoSmithKline plc
Johnson & Johnson Services, Inc
F. Hoffmann-La Roche AG
Boehringer Ingelheim International GmbH
Abbvie Inc
AstraZeneca
Pfizer, Inc
Clovis Oncology
Amgen Inc.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size 2019-2030
2.1.2 Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Ovarian Cancer Targeted Therapy Drugs by Country/Region, 2019, 2023 & 2030
2.2 Ovarian Cancer Targeted Therapy Drugs Segment by Type
2.2.1 PARP Inhibitors
2.2.2 Angiogenesis Inhibitors
2.2.3 Others
2.3 Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Type
2.3.1 Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Ovarian Cancer Targeted Therapy Drugs Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Drug Stores and Retail Pharmacy
2.4.3 Online Providers
2.5 Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Application
2.5.1 Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Player
3.1 Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Ovarian Cancer Targeted Therapy Drugs Revenue by Player (2019-2024)
3.1.2 Global Ovarian Cancer Targeted Therapy Drugs Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global Ovarian Cancer Targeted Therapy Drugs Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Ovarian Cancer Targeted Therapy Drugs by Region
4.1 Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Region (2019-2024)
4.2 Global Ovarian Cancer Targeted Therapy Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size Growth (2019-2024)
4.4 APAC Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size Growth (2019-2024)
4.5 Europe Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Country (2019-2024)
5.2 Americas Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Type (2019-2024)
5.3 Americas Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Region (2019-2024)
6.2 APAC Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Type (2019-2024)
6.3 APAC Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Country (2019-2024)
7.2 Europe Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Type (2019-2024)
7.3 Europe Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ovarian Cancer Targeted Therapy Drugs by Region (2019-2024)
8.2 Middle East & Africa Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Forecast
10.1 Global Ovarian Cancer Targeted Therapy Drugs Forecast by Region (2025-2030)
10.1.1 Global Ovarian Cancer Targeted Therapy Drugs Forecast by Region (2025-2030)
10.1.2 Americas Ovarian Cancer Targeted Therapy Drugs Forecast
10.1.3 APAC Ovarian Cancer Targeted Therapy Drugs Forecast
10.1.4 Europe Ovarian Cancer Targeted Therapy Drugs Forecast
10.1.5 Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Forecast
10.2 Americas Ovarian Cancer Targeted Therapy Drugs Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.2.2 Canada 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.2.3 Mexico 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.2.4 Brazil 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.3 APAC Ovarian Cancer Targeted Therapy Drugs Forecast by Region (2025-2030)
10.3.1 China Ovarian Cancer Targeted Therapy Drugs 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.3.3 Korea 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.3.4 Southeast Asia 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.3.5 India 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.3.6 Australia 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.4 Europe Ovarian Cancer Targeted Therapy Drugs Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.4.2 France 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.4.3 UK 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.4.4 Italy 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.4.5 Russia 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.5 Middle East & Africa Ovarian Cancer Targeted Therapy Drugs Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.5.2 South Africa 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.5.3 Israel 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.5.4 Turkey 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
10.6 Global Ovarian Cancer Targeted Therapy Drugs Forecast by Type (2025-2030)
10.7 Global Ovarian Cancer Targeted Therapy Drugs Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 Ovarian Cancer Targeted Therapy Drugs Forecast
11 Key Players Analysis
11.1 Merck KGaA
11.1.1 Merck KGaA Company Information
11.1.2 Merck KGaA Ovarian Cancer Targeted Therapy Drugs Product Offered
11.1.3 Merck KGaA Ovarian Cancer Targeted Therapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Merck KGaA Main Business Overview
11.1.5 Merck KGaA Latest Developments
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Company Information
11.2.2 GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs Product Offered
11.2.3 GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 GlaxoSmithKline plc Main Business Overview
11.2.5 GlaxoSmithKline plc Latest Developments
11.3 Johnson & Johnson Services, Inc
11.3.1 Johnson & Johnson Services, Inc Company Information
11.3.2 Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs Product Offered
11.3.3 Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Johnson & Johnson Services, Inc Main Business Overview
11.3.5 Johnson & Johnson Services, Inc Latest Developments
11.4 F. Hoffmann-La Roche AG
11.4.1 F. Hoffmann-La Roche AG Company Information
11.4.2 F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs Product Offered
11.4.3 F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 F. Hoffmann-La Roche AG Main Business Overview
11.4.5 F. Hoffmann-La Roche AG Latest Developments
11.5 Boehringer Ingelheim International GmbH
11.5.1 Boehringer Ingelheim International GmbH Company Information
11.5.2 Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs Product Offered
11.5.3 Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Boehringer Ingelheim International GmbH Main Business Overview
11.5.5 Boehringer Ingelheim International GmbH Latest Developments
11.6 Abbvie Inc
11.6.1 Abbvie Inc Company Information
11.6.2 Abbvie Inc Ovarian Cancer Targeted Therapy Drugs Product Offered
11.6.3 Abbvie Inc Ovarian Cancer Targeted Therapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Abbvie Inc Main Business Overview
11.6.5 Abbvie Inc Latest Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Information
11.7.2 AstraZeneca Ovarian Cancer Targeted Therapy Drugs Product Offered
11.7.3 AstraZeneca Ovarian Cancer Targeted Therapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 AstraZeneca Main Business Overview
11.7.5 AstraZeneca Latest Developments
11.8 Pfizer, Inc
11.8.1 Pfizer, Inc Company Information
11.8.2 Pfizer, Inc Ovarian Cancer Targeted Therapy Drugs Product Offered
11.8.3 Pfizer, Inc Ovarian Cancer Targeted Therapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Pfizer, Inc Main Business Overview
11.8.5 Pfizer, Inc Latest Developments
11.9 Clovis Oncology
11.9.1 Clovis Oncology Company Information
11.9.2 Clovis Oncology Ovarian Cancer Targeted Therapy Drugs Product Offered
11.9.3 Clovis Oncology Ovarian Cancer Targeted Therapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Clovis Oncology Main Business Overview
11.9.5 Clovis Oncology Latest Developments
11.10 Amgen Inc.
11.10.1 Amgen Inc. Company Information
11.10.2 Amgen Inc. Ovarian Cancer Targeted Therapy Drugs Product Offered
11.10.3 Amgen Inc. Ovarian Cancer Targeted Therapy Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Amgen Inc. Main Business Overview
11.10.5 Amgen Inc. Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.